UAE Becomes First Country to Approve AstraZeneca's Baxfendy for Resistant Hypertension
核心洞察
The UAE has become the first country worldwide to approve Baxfendy (搜索) (baxdrostat), a novel aldosterone synthase (搜索) inhibitor for treating resistant hypertension (搜索) in adults.
The drug offers response rates of 40-70% in patients previously unresponsive to other therapies by inhibiting aldosterone production rather than blocking its effects.
Clinical approval is supported by Phase III studies BaxHTN and Bax24, demonstrating statistically significant blood pressure reductions when used alongside standard therapies.
The United Arab Emirates has granted regulatory approval for AstraZeneca's Baxfendy (搜索) (baxdrostat), marking the first global authorization for this novel hypertension (搜索) treatment. The Emirates Drug Establishment (搜索) (EDE) approved the medication in 1mg and 2mg doses for adults with hypertension that remains uncontrolled despite existing antihypertensive medications.
Novel Mechanism Targets Aldosterone Production
Baxfendy (搜索) represents a significant departure from conventional hypertension (搜索) treatments through its unique mechanism of action. The drug functions as an aldosterone synthase (搜索) inhibitor, preventing the formation of aldosterone rather than blocking its effects after production. Dr. Salam Raad Bahjat Kashmoola, a family medicine consultant at Burjeel Medical City in Abu Dhabi, explained that the medication "inhibits the production of aldosterone, a hormone that causes the body to retain salt and water."
This targeted approach enables the body to eliminate excess fluid, relax blood vessels, and lower blood pressure by addressing the hormonal source of hypertension (搜索). "This breakthrough offers an important new option for patients whose hypertension remains dangerously elevated despite multiple medications," Dr. Kashmoola noted.
Clinical Evidence and Patient Response
The regulatory approval is supported by data from two Phase III clinical studies, BaxHTN and Bax24, which confirmed Baxfendy (搜索)'s efficacy as an adjunct to standard therapies. The studies demonstrated meaningful blood pressure reductions in patients with resistant or uncontrolled hypertension (搜索).
Clinical data indicates response rates ranging from 40 to 70 percent in patients previously unresponsive to other therapies. AstraZeneca reported that baxdrostat achieved "statistically significant and clinically meaningful reduction in systolic blood pressure in patients with resistant or uncontrolled hypertension (搜索)." The drug was found to achieve statistically significant reductions in blood pressure even in patients already taking other hypertension medications, with adverse effects typically being mild.
Addressing Growing Hypertension Burden
The approval comes amid rising concerns about hypertension (搜索) prevalence in the UAE. A 2025 study in the Journal of Hypertension found that 35.2 percent of Emiratis analyzed in Abu Dhabi had high blood pressure, compared to 24.5 percent around a decade earlier. The research warned that hypertension prevalence in Abu Dhabi was "high and increasing."
Additional studies have highlighted the scope of the problem across the Emirates. A household survey in Dubai in 2019 examining more than 2,500 adults found that 38 percent of men and 16 percent of women had high blood pressure. Research on University of Sharjah students published in 2021 revealed that almost one in five had "early hypertension (搜索)," often linked to lack of physical activity.
Regulatory and Clinical Significance
Dr. Fatima Al Kaabi, EDE director general, emphasized the approval's importance, stating: "Approving this treatment is yet another significant step towards enabling advanced medical solutions that precisely target disease pathways, particularly in cases that do not respond to traditional options, while ensuring uninterrupted access for patients."
The EDE indicated that the approval forms part of ongoing efforts to enhance pharmaceutical security and resilience, supporting a sustainable healthcare system in line with national priorities. This move underscores the UAE's objective to provide timely access to pharmaceutical innovations and implement adaptable regulatory frameworks that facilitate innovation.
Global Context and Future Prospects
AstraZeneca Gulf country president Sameh El Fangary highlighted the global significance of the approval: "The UAE's approval of Baxfendy (搜索) marks a significant step forward in expanding treatment options for hypertension (搜索) and reflects strong confidence in the scientific evidence supporting the therapy. We look forward to improving outcomes for patients."
The company has indicated that baxdrostat has been accepted for priority review by the US Food and Drug Administration as a potential treatment for adults whose other hypertension (搜索) medications have failed to control the condition. AstraZeneca noted that 1.4 billion people worldwide have hypertension, and in the United States, blood pressure remains uncontrolled in approximately half of patients on multiple medications.
Dr. Kashmoola described the drug as representing "a major shift in hypertension (搜索) treatment" due to its targeted approach to hormonal pathways. "This targeted approach could open a new pathway in cardiovascular and kidney protection, particularly for patients with resistant hypertension (搜索) who remain at high risk despite standard therapy," he explained.